EASD 2025 15 - 19 September 2025

Amycretin, a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist: Results of a phase 1b/2a clinical trial

Authors :

Kirsten Dahl¹; Kasper Adelborg²; Sohan Dey³; Ruben Duque do Vale²; Cassandra Key⁴; Søren Toubro²; Ania M. Jastreboff⁵

Affiliations

View Details Hide Details

Download poster (.pdf)

{{ getPageNum(PDFPage) }}

Keywords

Obesity

Congress oral presentation

GLP-1 RA

Amylin

Amycretin

PHASE 1 (RCT)

PHASE 2 (RCT)